Cipla partners with Serum Institute to provide vaccines in South Africa

 
Serum Institute manufactures a variety of vaccine classes including vaccines for polio, diphtheria, tetanus, BCG (tuberculosis), hepatitis B, measles, mumps and rubella; South Africa will be participating in the majority of these portfolios.
 
Michel Baijot, head of vaccines, Cipla Ltd, added, “This Cipla Medpro-SII agreement reflects again the complementarities of our two like-minded companies in bringing high quality, affordable vaccines to more countries.”
 
The agreement stipulates that Cipla Medpro will become the holder of all Medical Control Council (MCC) regulatory approvals such as product registrations and marketing authorisations. Cipla Medpro has exclusivity and first right of refusal of the Serum Institute pipeline within South Africa.

 
Adar Poonawalla, CEO and executive director, Serum Institute, commented, “SII is looking to extend the strong partnership it has with Cipla in Europe and India by working with Cipla Medpro in South Africa.”
 
Miller added, “We are confident that this agreement will support the Department of Health in rolling out its expanded immunisation program. Cipla Medpro will continuously look to partner with organisations that are aligned with the company’s ethos of advancing healthcare for all.”